Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq

Nicole A. Hawkins¹, Nicole J. Zachwieja¹, Alison R. Miller², Lyndsey L. Anderson¹, Jennifer A. Kearney¹,²*

¹ Department of Pharmacology Northwestern University Feinberg School of Medicine Chicago, Illinois, United States of America, ² Department of Medicine, Vanderbilt University, Nashville, Tennessee, United States of America

* jennifer.kearney@northwestern.edu

Abstract

A substantial number of mutations have been identified in voltage-gated sodium channel genes that result in various forms of human epilepsy. SCN1A mutations result in a spectrum of severity ranging from mild febrile seizures to Dravet syndrome, an infant-onset epileptic encephalopathy. Dravet syndrome patients experience multiple seizures types that are often refractory to treatment, developmental delays, and elevated risk for SUDEP. The same sodium channel mutation can produce epilepsy phenotypes of varying clinical severity. This suggests that other factors, including genetic, modify the primary mutation and change disease severity. Mouse models provide a useful tool in studying the genetic basis of epilepsy. The mouse strain background can alter phenotype severity, supporting a contribution of genetic modifiers in epilepsy. The Scn1a+/− mouse model has a strain-dependent epilepsy phenotype. Scn1a+/− mice on the 129S6/SvEvTac (129) strain have a normal phenotype and lifespan, while [129xC57BL/6J]F1-Scn1a+/- mice experience spontaneous seizures, hyperthermia-induced seizures and high rates of premature death. We hypothesize the phenotypic differences are due to strain-specific genetic modifiers that influence expressivity of the Scn1a+/- phenotype. Low resolution mapping of Scn1a+/- identified several Dravet syndrome modifier (Dsm) loci responsible for the strain-dependent difference in survival. One locus of interest, Dsm1 located on chromosome 5, was fine mapped to a 9 Mb region using interval specific congenics. RNA-Seq was then utilized to identify candidate modifier genes within this narrowed region. Three genes with significant total gene expression differences between 129S6/SvEvTac and [129xC57BL/6J]F1 were identified, including the GABA_A receptor subunit, Gabra2. Further analysis of Gabra2 demonstrated allele-specific expression. Pharmacological manipulation by clobazam, a common anticonvulsant with preferential affinity for the GABRA2 receptor, revealed dose-dependent protection against hyperthermia-induced seizures in Scn1a+/- mice. These findings support Gabra2 as a genetic modifier of the Scn1a+/- mouse model of Dravet syndrome.
Author Summary

Epilepsy is a neurological disorder affecting approximately 3 million Americans and 1% of the worldwide population. Approximately 70% of patients diagnosed with epilepsy have a genetic basis for their disease. The same genetic mutation can result in epilepsy with varying clinical severity in some individuals. This suggests that additional factors modify the effect of the primary mutation, resulting in the differences observed. Mouse models of epilepsy also exhibit variable severity depending on the inbred strain background. This is a useful model system that enables us to determine other genetic factors that influence phenotype presentation. This study investigates a mouse model of Dravet syndrome. Similar to Dravet syndrome patients, the mice experience a variety of seizure types and have increased risk for premature death. Interestingly, the Dravet syndrome phenotype is completely masked on one mouse strain background. Through a series of genetic and pharmacological techniques we were able to identify a gene that is likely responsible for the strain-dependent phenotype difference of Dravet mice. Identifying genes that modify diseases can help predict patient outcomes and suggest new therapies for the treatment of epilepsy.

Introduction

Epilepsy is one of the most common neurological disorders, affecting approximately 50 million people worldwide. Approximately two-thirds of human epilepsies are presumed to have a genetic basis. Voltage-gated sodium channel gene mutations are the most common cause of monogenic epilepsy. Mutations in SCN1A, encoding Nav1.1, result in a broad spectrum of disorders ranging from simple febrile seizures to Dravet syndrome, a severe, infant-onset epileptic encephalopathy with devastating outcomes [1]. Dravet syndrome patients have multiple seizure types that are refractory to treatment, as well as delays of psychomotor and cognitive development and a high risk of sudden unexpected death in epilepsy (SUDEP) [2].

Within genetic epilepsies, diverse phenotypes often result from identical sodium channel mutations [3]. This suggests that disease severity is influenced by other factors, including genetic modifiers. The genetic basis of epilepsy can be studied using mouse models that recapitulate hallmark features of human epilepsies. Frequently, mutations that result in seizures show strain-dependent phenotype variability, suggesting a contribution of genetic modifiers in epilepsy [4]. Heterozygous deletion of mouse Scn1a models features of Dravet syndrome, including spontaneous seizures, thermal seizure sensitivity, cognitive deficits, and increased mortality [5,6]. Interestingly, expressivity of the Scn1a+/− phenotype is highly strain-dependent. When the Scn1a+/− mutation is maintained on the 129S6/SvEvTac (129) strain, 129. Scn1a+/− mice have no overt phenotype and a normal lifespan. When 129.Scn1a+/− mice are crossed with C57BL/6J (B6), the resulting [129xB6]F1.Scn1a+/− (F1.Scn1a+/−) offspring exhibit spontaneous seizures and 75% mortality by 8 weeks of age [7]. We previously mapped several Dravet syndrome modifier (Dsm) loci that influence the strain-dependent difference in survival [7].

In the current study, we used interval-specific congenic (ISC) strains to confirm and fine map the Dsm1 locus on chromosome 5. We then performed candidate gene analysis using an RNA-Seq approach, and identified Gabra2 as a high priority candidate gene. Further evaluation of Gabra2 by expression analysis and pharmacological manipulation support Gabra2 as a putative modifier gene that influences survival in the Scn1a+/− Dravet model.
Inheritance of B6 alleles in Dsm1 increased the risk of early death in Scn1a +/- mice [7]. Low resolution mapping identified the Dsm1 1.5 LOD support interval as 27.3–41.3 cM on chromosome 5, with a peak at 34 cM [7]. To refine the Dsm1 map interval, five interval specific congenic (ISC) lines were generated with varying 129-derived chromosome 5 segments within Dsm1 on a congenic B6 background (Fig 1A). Each ISC line was crossed with 129.Scn1a +/- to generate F1.Scn1a +/- offspring carrying either homozygous (129/129) or control heterozygous (129/B6) alleles in Dsm1. Survival of F1.Scn1a +/- mice was then monitored until 8 weeks of age (Fig 1B).

A significant improvement in survival was observed with lines ISC-A (4–118 Mb; p < 0.01), ISC-B (4–74.9 Mb; p < 0.0001), ISC-C (53–118 Mb; p < 0.05) and ISC-D (64.6–74.9 Mb; p < 0.0002) (Fig 1B). The strongest effect on survival was observed in mice carrying homozygous 129/129 alleles in ISC-B and ISC-D, with 8 week survival of 91.3% and 92.8%, respectively, compared to only 28.5% in heterozygous F1.KO control mice (ISC-D: 0.024 ± 0.015 seizures/hr; F1 control: 0.022 ± 0.02 seizures/hr). Dissociation of the survival and seizure frequency phenotypes was somewhat surprising, and raised the
question of whether seizure frequency and survival are correlated in F1.Scn1a+/− mice. To address this question, we examined a separate phenotyping cohort and determined seizure counts for F1.Scn1a+/− mice between P19 to P24. In F1.Scn1a+/− mice experiencing seizures, total numbers of seizures were compared with survival throughout the monitoring period (Survivors: 7.95 ± 1.42 seizures; Lethals: 5.13 ± 1.55 seizures). This comparison revealed that high seizure frequency did not correlate with premature lethality in F1.Scn1a+/− (Pearson r² = 0.01, p > 0.8111), consistent with our observations with ISC-D.

Candidate Gene Identification by RNA-Seq

The Dsm1 locus was narrowed to a 9 Mb region that contains 109 known and predicted genes, of which 40 are known to be expressed in the brain (Fig 2A). Within that interval, we identified four genes with non-synonymous coding sequence differences: Phox2b, Tmem33, Slc30a9, and Fryl. All resulting amino acid differences were predicted to be tolerated by SIFT [8].

To assess expression differences between 129 and [129xB6]F1 strains, we performed RNA-Seq on hippocampal RNA isolated from wildtype 129 and [129xB6]F1 mice at P24. Within the Dsm1 interval, RNA-Seq identified three genes, Nsun7, Bend4 and Gabra2, with significant expression differences between the 129 and [129xB6]F1 strains (Fig 2B, S1 Table). Nsun7 is a putative RNA methyltransferase that when mutated, leads to reduced sperm motility in humans and mice [9,10]. Bend4, or BEN domain containing 4, is of unknown function. Gabra2 encodes the GABA_A receptor α2 subunit, which has previously been associated with addiction and dependence [11–13]. Considering the importance of GABA signaling in epilepsy and reported dysfunction in GABAergic signaling in Dravet syndrome [14–16], Gabra2 was identified as the top candidate modifier gene at Dsm1. Expression of Gabra2 was significantly elevated in wildtype 129 mice compared to [129XB6]F1 mice (Fig 2B).

Candidate Gene Expression Analysis

We further evaluated forebrain Gabra2 transcript and protein expression in ISC-D mice carrying homozygous 129/129, heterozygous 129/B6 or homozygous B6/B6 alleles in Dsm1. We used digital droplet RT-PCR (ddRT-PCR) to evaluate transcript expression of Gabra2, as well as expression of other GABA_A receptor genes located within Dsm1, including Gabra4, Gabrb1 and Gabrg1. Gabra2 expression was significantly different between all genotypes (F2,15 = 206.4, p < 0.0001). We observed the highest levels of Gabra2 transcript with homozygosity for 129 alleles in Dsm1, intermediate levels with heterozygosity, and the lowest levels with B6 homozygosity (Fig 3A). Transcript expression of the other Gabr genes in the interval did not differ between genotypes (S1 Fig). Relative GABRA2 protein expression determined by immunoblotting correlated with the transcript levels, showing the highest expression with homozygous 129 alleles in Dsm1, intermediate with heterozygous alleles, and lowest with B6 homozygosity (Fig 3B and 3C). These results demonstrate that the level of Gabra2 expression is regulated by alleles within the Dsm1 interval, and that high expression of Gabra2 is correlated with the protective allele for Scn1a+/− survival.

Pharmacological Modulation of Gabra2

We used clobazam, an anticonvulsant drug that has preferential affinity for the GABRA2 subunit [17–19], as a pharmacological tool to further evaluate Gabra2 as a candidate modifier gene. Both Dravet syndrome patients and F1.Scn1a+/− Dravet mice experience seizures triggered by hyperthermia. We evaluated the effect of clobazam on survival and hyperthermia seizure threshold in F1.Scn1a+/− mice. Beginning at P18, F1.Scn1a+/− mice were fed either chow containing clobazam (320 mg per kg of chow; estimated dosage 40 mg/kg/day) or control
chow, and survival was monitored to 30 days of age. This dose of clobazam, selected to achieve plasma concentrations within the human therapeutic range, was not sufficient to provide protection against survival. We used the hyperthermia-induced seizure assay to perform an acute dose-response study. Between P14–16, F1.\textit{Scn1a}+/− mice received an intraperitoneal injection of vehicle or clobazam (0.3, 1, or 30 mg/kg) prior to the induction of hyperthermia. Clobazam administration provided dose-dependent protection against hyperthermia-induced seizures (Fig 4). Clobazam dosed at 30 mg/kg provided complete protection against hyperthermia-induced seizures, while 83% of vehicle controls experienced GTC seizures with an average threshold temperature of 42.3°C (p < 0.0006). Clobazam doses of 0.3 and 1 mg/kg significantly

\[\text{Fig 2. Evaluation of Dsm1 Candidate Genes by RNA-Seq. A. The refined map interval is shown with mouse RefSeq gene annotations. The genes with strain-dependent differential expression are indicated by grey shading (Ensembl Mouse GRCm38.p4)[53]. B. Three genes within the Dsm1 interval showed significant differences in brain expression between wildtype 129 and [129xB6]F1 mice: Gabra2 (q < 0.0029**), Nsun7 (q < 0.02*), and Bend4 (q < 0.02*). Shown are RNA-Seq FPKM values and 95% confidence intervals calculated by String Tie. q-values are false discovery rate-adjusted p-values.} \]

doi:10.1371/journal.pgen.1006398.g002
increased GTC seizure thresholds to 43.0°C ($p < 0.0022$) and 42.9°C ($p < 0.0079$), respectively.

To ensure plasma concentrations of clobazam reflected the human therapeutic range (0.1−0.4 μg/mL), plasma samples were assayed by HPLC. The commonly cited clobazam rodent dose of 30 mg/kg [20–22] resulted in an average plasma concentration that was 15 times higher (5.84 μg/mL) than the human therapeutic range, while the 1 mg/kg dose resulted in an average plasma concentration (0.16 μg/mL) within the range. Plasma concentrations were below the detection limit of the HPLC assay following the 0.3 mg/kg dose.

Discussion

Candidate gene and expression analysis, along with pharmacological testing, identified Gabra2 as a putative modifier gene that influences survival in the Scn1a+/− Dravet mouse model. Considering the significance of GABAergic pathways in relation to epilepsy, strain-specific expression of Gabra2 may differentially influence excitatory/inhibitory balance. Several GWAS studies have demonstrated that human GABRA2 genetic variants are associated with alcohol dependence [23–27]. However, to date, no GABRA2 genetic variants have been associated with human epilepsy. Altered GABRA2 transcript and protein expression has observed in a number of rodent seizure models and patients with focal cortical dysplasia, tuberous sclerosis and temporal lobe epilepsy, suggesting a potential link between GABRA2 expression and epilepsy [28–32]. There is evidence for variation in human cortical GABRA2 expression that is associated with a trans eQTL on chromosome Xp11.4 [33]. Our mouse RNA-Seq and expression analysis demonstrated that low Gabra2 expression associated with the B6 allele and correlated with reduced survival in the Scn1a+/− model. Previous work has shown that in some mouse strains, Gabra2 expression is strongly modulated by a cis eQTL that overlaps with Dsm1 and a trans eQTL on chromosome 10 [34]. The difference in Gabra2 expression was maintained when we examined transcript and protein levels in brain tissues from the ISC-D line, which contains 129 alleles only in the minimal interval and is B6 elsewhere in the genome. From this, we infer that Gabra2 expression difference arises from a local eQTL effect within the Dsm1 interval. This is supported by a recent study that demonstrated differential allele expression of Gabra2 transcript in B6/129SF1 mice, with the 129 allele expressed at 2−3 times the level of the B6 allele [35]. Future work will focus on identifying the responsible regulatory variants within the Gabra2 genomic region.

The failure of line ISC-D to reduce seizure frequency in F1.Scn1a+/− mice was not surprising. As we report here, and have observed in our previous studies, high seizure counts do not correlate with premature death in F1.Scn1a+/− mice. Therefore, we could exclude the survival improvement of the ISC-D line to be a result of altered seizure frequency. GABAergic neurons

---

Table 1. Coding sequence variants between C57BL/6J and 129S6/SvEvTac in Dsm1 region.

| Location* | Gene | Description | Variant | Consequence | SNP ID |
|-----------|------|-------------|---------|-------------|--------|
| Chr 5:67096280 | Phox2b | paired-like homeobox 2b | G/A | Ala/Thr | - |
| Chr 5:67263874 | Tmem33 | Transmembrane protein 33/Shinc3 | C/T | Ala/Val | rs29520321 |
| Chr 5:67264487 | Tmem33 | Transmembrane protein 33/Shinc3 | T/C | Phe/Leu | rs29510937 |
| Chr 5:67324174 | Slc30a9 | solute carrier family 30 (zinc transporter), member 9/GAC63 | T/C | Val/Ala | rs29548855 |
| Chr 5:73064826 | Fryl | FRY like transcription coactivator | G/A | Gly/Ser | rs33085471 |
| Chr 5:73076182 | Fryl | FRY like transcription coactivator | C/T | Ala/Val | rs29682128 |
| Chr 5:73220556 | Fryl | FRY like transcription coactivator | G/C | 5' UTR variant | rs29683841 |

*Denotes location in GRCm38.p4 genome assembly.
Fig 3. Allele specific Gabra2 transcript and protein expression. A. Relative brain Gabra2 transcript levels between mice carrying 129/129, 129/B6 or B6/B6 alleles in ISC-D were determined by ddRT-PCR and expressed as a ratio of Gabra2 to Tbp. Highest levels of Gabra2 transcript are observed with homozygous 129/129 alleles, intermediate levels with heterozygosity, and lowest levels with B6 homozygosity. B and C. Brain GABRA2 protein expression for mice carrying 129/129, 129/B6 or B6/B6 alleles in ISC-D was assayed by immunoblotting using a rabbit polyclonal antibody for GABRA2.
are found in several brain regions involved in the control of respiration and cardiac activity, and dysfunction in either pathway is believed to be primarily responsible for SUDEP [36–39]. Mice with a conditional Scn1a<sup>+/−</sup> deletion in forebrain GABAergic interneurons experience SUDEP and cardiac dysfunctions similar to the Dravet Scn1a<sup>+/−</sup> mouse model [40]. When Scn1a<sup>+/−</sup> was conditionally deleted in the heart, the phenotype was not observed, demonstrating that SUDEP observed in Scn1a<sup>+/−</sup> mice originates from the central nervous system [40].

Increased expression of GABRA2 may exert a protective effect by altering autonomic control of cardiac and/or respiratory function and may explain the improved survival observed with 129/129 homozygosity in ISC-D. Additionally, GABA<sub>A</sub> receptor activity plays a pivotal role in neuronal development and altered levels of Gabra2 during development may alter network excitability [41].

Interestingly, clobazam, which has preferential affinity for the GABRA2 subunit, offers some therapeutic benefit in Dravet syndrome patients [17–19,42,43]. In our studies, threshold temperature for hyperthermia-induced seizures was elevated in Scn1a<sup>+/−</sup> mice treated with supratherapeutic levels of clobazam, while lower doses did not provide significant protection.

![Figure 4](https://doi.org/10.1371/journal.pgen.1006398.g003)

**Fig 4.** Pharmacological modulation of Gabra2 by clobazam. F1 Scn1a<sup>+/−</sup> mice underwent hyperthermia-induced seizure threshold testing after IP injections of vehicle or clobazam. The temperature at which generalized tonic-clonic seizure activity occurred is shown. Clobazam administration provided dose-dependent protection against hyperthermia-induced seizures. P values were determined by Mantel-Cox log-rank test (**p<0.01; ***p<0.001).
from hyperthermia-induced seizures or premature death. The 30mg/kg clobazam dose provided complete protection against hyperthermia-induced seizures, but resulted in plasma levels far above the human therapeutic range, highlighting the necessity of determining drug concentrations in similar studies. Frequently, Dravet syndrome patients are prescribed stiripentol as an add-on treatment to clobazam. In a randomized placebo-controlled study in children with Dravet syndrome, 71% of patients treated with a combination of clobazam and stiripentol experienced a reduction in seizure frequency [44]. Although the mechanism of action for the anticonvulsant benefit of stiripentol is yet to be determined, stiripentol has been identified as an inhibitor of CYP450s, specifically CYP3A4 and more potently CYP2C19, both important for the metabolism of clobazam. *In vivo*, a significant increase in the plasma concentrations of both clobazam and its active metabolite N-desmethylclobazam has been shown with concomitant stiripentol treatment [45], suggesting that elevated levels of clobazam may account for some of the therapeutic benefit.

Identification of Gabra2 as a putative modifier gene at the Dsm1 locus furthers our understanding of the genetic basis of Dravet syndrome. This provides information that may help predict the risk of SUDEP and the clinical course of epilepsy due to a sodium channel mutation. Furthermore, modifier genes may suggest new targets for the improved treatment of epilepsy.

**Methods**

**Ethics Statement**

All studies were approved by the Vanderbilt University [M/06/499 JAK] and Northwestern University Animal Care and Use Committees [IS00000539 JAK] in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Principles outlined in the ARRIVE (Animal Research: Reporting of in vivo Experiments) guideline and Basel declaration (including the 3R concept) were considered when planning experiments.

**Mice**

Scn1atm1Kea mice, with deletion of the first coding exon, were generated by homologous recombination in TL1 ES cells (129S6/SvEvTac) as previously described [7]. The 129.Scn1atm1 line has been maintained by continuous backcrossing to 129S6/SvEvTac (129). To generate mice for hyperthermia-induced seizure experiments, 129.Scn1a+/- mice were crossed with C57BL/6J (B6) resulting in [129XB6]F1. Scn1a+/- (F1.Scn1a+/-) mice. Mice were maintained in a Specific Pathogen Free (SPF) barrier facility with access to food and water *ad libitum*.

**Generation of Interval Specific Congenic (ISC) lines**

We generated five ISC lines carrying 129-derived chromosome 5 segments on a B6 background. [129 x B6]F1 progeny were continually backcrossed to B6 to generate congenic lines. Genotyping for chromosome 5 markers was performed at each generation and animals retaining 129 alleles in the Dsm1 interval were propagated. Whole genome and selective genotyping was performed at generations N2–N7 to select breeders with the lowest percentage of 129 alleles in the rest of the genome. All ISC lines were backcrossed to B6 for ≥N6 generations prior to experiments.

**Phenotyping**

Dsm1 ISC females were crossed with heterozygous Scn1a+/- males to generate (B6.ISC x 129. Scn1a+/-)F1 offspring carrying heterozygous (129/B6) or homozygous (129/129) alleles in Dsm1. Phenotyping was performed similarly to our low-resolution mapping study [7]. Mice
were ear-tagged at P12–14. At P21, mice were weaned into holding cages containing four to five mice of the same age and sex. Wild-type littermates were included in all holding cages. Survival was monitored to 8 weeks of age. During that time, all mice were monitored daily for general health and any mouse visibly unhealthy (e.g. underweight, dehydrated, poorly groomed, or immobile) was euthanized and excluded from the study. The focus of the study was sudden and unexpected death in the Scn1a+/− mice occurring in otherwise healthy appearing animals.

We used continuous video monitoring to determine GTC seizure frequency in Scn1a+/− mice with homozygous or heterozygous alleles in ISC-D mice. At P20, mice were placed in a recording chamber and video was captured using a Day/Night camera (Samsung SCB5003) equipped with an infrared lens (Tamron 13FG04IRSQ) and saved to a DVR (Samsung SRD-876D). During recording, mice had ad libitum access to food and water, and were maintained on a 14:10 light-dark cycle. Video records were analyzed offline by an observer blinded to genotype. We validated use of video capture for seizure evaluation in Scn1a+/− mice in a preliminary study. Behavioral GTC seizures were correlated with electroencephalographic seizures using video-electroencephalography (EEG) monitoring as previously described. On P16, F1 Scn1a+/− mice were implanted with prefabricated headmounts (Pinnacle Technology, Inc., Lawrence, KS, USA) and mice were allowed to recover for >72 hours. Continuous video-EEG data monitoring was performed from P20-P26. Data were acquired and analyzed with Sirenia software (Pinnacle Technology, Inc.). Electrographic GTC seizure activity was scored manually using video-EEG data. Separately, behavioral GTC seizures were counted using only the video record. There was perfect agreement between the video-EEG and video-only results (κ = 1.0; n = 25 mice; 39 seizures), validating video recording as a reliable method for measuring GTC seizure frequency in Scn1a+/− mice.

Genotyping

DNA was prepared from tail biopsies using the Gentra Puregene Mouse Tail Kit according to the manufacturer’s instructions (Qiagen, Valencia, CA, USA). Scn1a genotype was determined by multiplex PCR as previously described [7]. Microsatellite genotyping was performed by analysis of PCR products on 7% denaturing polyacrylamide gels stained with ethidium bromide.

RNA-Seq

Hippocampi were dissected from 129 and [129 x B6]F1 mice at P24. Primary pools were created with tissue from both male (n = 2) and female (n = 2). Total RNA was isolated using TRIzol reagent according to the manufacturer’s instructions (Life Technologies). Following RNA isolation, RNA integrity was assessed and all samples had a RIN of ≥ 7.7. For each strain, three superpooled biological replicates were generated by combining total RNAs from 3–4 primary pools (n = 12–16 mice/superpool). RNA integrity was assessed on the superpool samples and all samples had a RIN of ≥ 8.1.

Samples were processed for RNA-Seq using the TruSeq RNA Library Preparation Kit v2 (Illumina, San Diego, CA, USA). Samples were sequenced on an Illumina HiSeq 4000 at BGI (Hong Kong, China). Three multiplexed lanes of 50-bp single-end sequencing resulted in almost 167 million mapped reads. Base calling and filtering of sequence reads were performed with the Illumina pipeline [46]. Bioinformatic analysis was performed using Tuxedo Tools on the GALAXY platform [47–49]. Tophat2 aligned reads with Bowtie2 and identified splice junctions [50]. StringTie assembled alignments into transcripts [51]. Cuffmerge and Cuffcompare combined biological replicate transcript files and assigned reference annotations to transcripts [52]. Cuffdiff provided significance values for expressed genes and transcripts [52].
**ddRT-PCR**

Forebrain RNA was extracted from P24 ISC-D mice carrying homozygous B6, homozygous 129, or heterozygous alleles. Total RNA was isolated using TRIzol reagent according to the manufacturer’s instructions. First-strand cDNA was synthesized from 2 micrograms of RNA using oligo(dT) primer and Superscript IV reverse transcriptase according to the manufacturer’s instructions (Life Technologies). First-strand cDNA samples were diluted 1:10 and 5 μl was used as template. Quantitative digital droplet PCR (ddPCR) was performed using ddPCR Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA, USA) and TaqMan Gene Expression Assays (Life Technologies) for mouse Gabra2 (FAM-MGB-Mm00433435_m1), Gabra4 (FAM-MGB-Mm00802631_m1), Gabrb1 (FAM-MGB-Mm00433461_m1), Gabrg1 (FAM-MGB-Mm00439047_m1) and Tbp (VIC-MGB-Mm00446971_m1). Reactions were partitioned into 20,000 droplets (1 nL each) in a QX200 droplet generator (Bio-Rad). Thermocycling conditions were 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute (ramp rate of 2°C/sec) and a final inactivation step of 98°C for 10 minutes. Following amplification, droplets were analyzed with a QX200 droplet reader with QuantaSoft v1.6.6.0320 software (Bio-Rad). All assays lacked detectable signal in no-RT and no template controls. Relative transcript levels were expressed as a ratio of the gene of interest concentration to Tbp concentration. Statistical comparison between groups was made using ANOVA with Tukey’s post-hoc tests. Data are presented as mean ± SD of 5–6 biological replicates.

**Immunoblotting**

Forebrain membrane proteins were isolated from P24 ISC-D mice carrying homozygous B6, homozygous 129, or heterozygous alleles. Membrane fractions (50 μg/lane) were separated on a 7.5% SDS-PAGE gel and transferred to nitrocellulose membranes. Immunoblots were probed for GABRA2 using a rabbit polyclonal antibody (Phosphosolutions, 822-GA2C) and for Moltalin using a mouse monoclonal antibody (NeuroMab, 75–127). Alexa-conjugated fluorescent secondary antibodies (Jackson ImmunoResearch) were used to detect bound primary antibody using an Odyssey imaging system (Licor).

**Hyperthermia Induced Seizures**

F1.Scn1a<sup>+/−</sup> mice between P14 to P16 received an intraperitoneal injection of 0, 0.3, 1, or 30 mg/kg doses of clobazam solubilized in vegetable oil (10 ml/kg volume). After 15 minutes, each mouse was placed in a cylindrical container and fitted with a RET-3 rectal probe (Physitemp) connected to a heat lamp via a temperature controller (TCAT-2DF (Physitemp) reconfigured with a Partlow 1160+ controller). At 20 minutes post-injection, mouse body temperature was elevated by 0.5°C every two minutes until a maximum of 42.5°C was reached. When a GTC seizure occurred (rearing and falling with forelimb clonus), mice were removed from the container and temperature was recorded. If after 3 minutes at 42.5°C no seizure occurred, the mouse was removed and recorded as a seizure-free.

**Clobazam Assay by HPLC**

Mice that underwent hyperthermia-induced seizure threshold testing were immediately removed from the assay and anesthetized with isoflurane. Cardiac puncture was performed and whole blood was collected in heparin microtainers (BD365965). Plasma was isolated by centrifugation (9000 x g for 10 minutes at 4°C). Plasma samples (50–100 μL) were spiked with 5 μg/mL prazepam (250 μg/mL in methanol) as an internal standard and vortexed well. Extraction of clobazam and prazepam was achieved by vortex-mixing with diethyl ether (4x volume).
The organic layer was isolated following centrifugation at 2000 rpm for 5 minutes and was evaporated by heating at 75°C. The residue was reconstituted in acetonitrile:20 mM potassium phosphate buffer, pH 7 (42:58, v/v).

Clobazam was detected in plasma samples using a HPLC Flexar Binary LC Pump Platform and Flexar UV/Vis Detector (Perkin Elmer, Waltham, MA) with a Polaris C-18 A 5 μm column (4.6 x 100 mm; Agilent Technologies, Santa Clara, CA). The mobile phase consisted of acetonitrile and 20 mM potassium phosphate, pH7 (42:58, v/v) with a flow rate of 1.5 mL/min and detection at a wavelength of 228 nm. Quantitative analysis clobazam was performed using a calibration curve (0.05–1.0 μg/mL) by spiking clobazam into blank mouse plasma and preparing as described above.

Supporting Information

S1 Fig. GABR subunit expression analysis. Brain Gabr transcript levels were compared between mice carrying 129/129, 129/B6 or B6/B6 alleles in ISC-D as determined by ddRT-PCR. Transcript levels are expressed relative to Tbp for Gabra4 (A), Gabrb1 (B), and Gabrg1 (C). For all three genes, no difference in transcript levels were observed between homozygous 129/129, heterozygous 129/B6 or homozygous B6/B6. Scatter plot data points represent samples from individual mice (n = 5–7 biological replicates). Average values are depicted as a horizontal bar and error bars represent the SD. Statistical comparison between groups was made using ANOVA with Tukey’s post-hoc tests.

S1 Table. Cuffdiff output for Dsm1 region on mouse chromosome 5.

Acknowledgments

We thank Stephen J. Moss for providing the GABRA2 antibody, Alfred L. George, Jr. for helpful discussions, and Clint McCollom for mouse colony support.

Author Contributions

Conceptualization: NAH JAK.
Formal analysis: NAH ARM JAK.
Funding acquisition: JAK.
Investigation: NAH ARM NJZ LLA JAK.
Methodology: NAH ARM LLA JAK.
Project administration: JAK.
Supervision: JAK.
Visualization: NAH ARM NJZ JAK.
Writing – original draft: NAH JAK.
Writing – review & editing: NAH ARM NJZ LLA JAK.
References

1. Meisler MH, Kearney JA (2005) Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 115: 2010–2017. doi: 10.1172/JCI25466 PMID: 16075041

2. Dravet C (2011) The core Dravet syndrome phenotype. Epilepsia 52 Suppl 2: 3–9. doi: 10.1111/j.1528-1167.2011.02994.x PMID: 21463272

3. Meisler MH, O'Brien JE, Sharkey LM (2010) Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol 588: 1841–1848. doi: 10.1113/jphysiol.2010.188482 PMID: 20351042

4. Kearney JA (2011) Genetic modifiers of neurological disease. Curr Opin Genet Dev 21: 349–353. doi: 10.1016/j.gde.2010.12.007 PMID: 21251811

5. Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, et al. (2007) Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 27: 5903–5914. doi: 10.1523/JNEUROSCI.5270-06.2007 PMID: 17537961

6. Yu FH, Mantegazzam M, Westenbroek RE, Robbins CA, Kalume F, et al. (2006) Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9: 1142–1149. doi: 10.1038/nn1754 PMID: 16921370

7. Miller AR, Hawkins NA, McCollohm CE, Kearney JA (2014) Mapping genetic modifiers of survival in a mouse model of Dravet syndrome. Genes, Brain and Behavior 13: 163–172.

8. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073–1081. doi: 10.1038/nprot.2009.86 PMID: 19561590

9. Harris T, Marquez B, Suarez S, Schimenti J (2007) Sperm Motility Defects and Infertility in Male Mice with a Mutation in Nsun7, a Member of the Sun Domain-Containing Family of Putative RNA Methyltransferases. Biology of Reproduction 77: 376–382. doi: 10.1095/biolreprod.106.058669 PMID: 17442852

10. Khosronezhad N, Hosseinzadeh Colagar A, Mortazavi S (2015) The Nsun7 (A11337)-deletion mutation, causes reduction of its protein rate and associated with sperm motility defect in infertile men. Journal of Assisted Reproduction and Genetics 32: 807–815. doi: 10.1007/s10815-015-0443-0 PMID: 25702163

11. Arias AJ, Covault J, Feinn R, Pond T, Yang B-Z, et al. (2014) A GABRA2 Variant Is Associated with Increased Stimulation and ‘High’ Following Alcohol Administration. Alcohol and Alcoholism 49: 1–9. doi: 10.1093/alcalc/agt163 PMID: 24166645

12. Holtzeg MM, Villafuerte S, Weiland BJ, Enoch M-A, Burmeister M, et al. (2014) Effect of GABRA2 Genotype on Development of Incentive-Motivation Circuitry in a Sample Enriched for Alcoholism Risk. Neuropsychopharmacology 39: 10877–10886. doi: 10.1038/npp.2014.161 PMID: 24975023

13. Lieberman R, Kranzler HR, Joshi P, Shin D-G, Covault J (2015) GABRA2 Alcohol Dependence Risk Allele is Associated with Reduced Expression of Chromosome 4p12 GABAA Subunit Genes in Human Neural Cultures. Alcoholism: Clinical and Experimental Research 39: 1654–1664.

14. Mistry AM, Thompson CH, Miller AR, Vanoye CG, George AL Jr., et al. (2014) Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice. Neurobiol Dis 65: 1–11. doi: 10.1016/j.nbd.2014.01.006 PMID: 24434335

15. Oakley JC, Kalume F, Catterall WA (2011) Insights into pathophysiology and therapy from a mouse model of Dravet syndrome. Epilepsia 52: 59–61. doi: 10.1111/j.1528-1167.2011.03004.x PMID: 21463282

16. Xia G, P. Pourali S, Warner TA, Zhang C-Q, L. Macdonald R, et al. (2016) Altered GABAA receptor expression in brainstem nuclei and SUDEP in Gabrg2+/-/- mice associated with epileptic encephalopathy. Epilepsy Research 123: 50–54. doi: 10.1016/j.eplepsres.2016.04.002 PMID: 27131289

17. Nakajima H (2001) [A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. Nihon Yakuriga ku Zasshi 118: 117–122. PMID: 11530681

18. Sankar R (2012) GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam. CNS Drugs 26: 229–244. doi: 10.2165/11599020-0000000000000000 PMID: 22145708

19. Jensen HS, Nichol K, Lee D, Ebert B (2014) Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for alpha2- versus alpha1-GABA(A)-receptor complexes. PLoS One 9: e88456. doi: 10.1371/journal.pone.0088456 PMID: 24533090

20. Besson M, Daali Y, Di Lio A, Dayer P, Zeilhofer HU, et al. (2013) Antihyperalgesic effect of the GABA (A) ligand clobazam in a neuropathic pain model in mice: a pharmacokinetic-pharmacodynamic study. Basic Clin Pharmacol Toxicol 112: 192–197. doi: 10.1111/bcpt.12017 PMID: 23966671
21. Florek-Luszczki M, Zagaja M, Luszczki JJ (2015) Influence of arachidonyl-2'-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute side-effect potentials of clobazam, lacosamide, and pregabalin in the maximal electroshock-induced seizure model and chimpney test in mice. Fundamental & Clinical Pharmacology 29: 382–393.

22. Luszczki JJ, Trojnar MK, Ratnaraj N, Patsalos PN, Czuczwar SJ (2010) Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model and chimney test in mice. Epilepsy Research 90: 188–198. doi: 10.1016/j.eplepsyres.2010.04.006 PMID: 20493662

23. Covault J, Gelernter J, Hesselbrock V, Nelligan M, Kranzler HR (2004) Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 129B: 104–109. doi: 10.1002/ajmg.b.30091 PMID: 16395124

24. Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, et al. (2004) Variation in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, is associated with alcohol dependence and with brain oscillations. Am J Hum Genet 74: 705–714. doi: 10.1086/383283 PMID: 15024690

25. Fehr C, Sander T, Tadic A, Lenzen KP, Anghelescu I, et al. (2006) Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr Genet 16: 9–17. PMID: 16395124

26. Lappalainen J, Krupitsky E, Remizov M, Pchelina S, Taraskina A, et al. (2005) Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res 29: 493–498. PMID: 15834213

27. Soyka M, Preuss UW, Hesselbrock V, Zil P, Koller G, et al. (2008) GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. J Psychiatr Res 42: 184–191. doi: 10.1016/j.jpsychires.2008.01.006 PMID: 18562204

28. Bethmann K, Fritschy JM, Brandt C, Loscher W (2008) Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis 31: 169–187. doi: 10.1016/j.nbd.2008.01.005 PMID: 18562204

29. Crino PB, Duhaime AC, Baltuch G, White R (2001) Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia. Neurology 56: 906–913. PMID: 11294928

30. Drexel M, Kirchmair E, Sperk G (2013) Changes in the expression of GABAA receptor subunit mRNAs in parahippocampal areas after kainic acid induced seizures. Front Neural Circuits 7: 142. doi: 10.3389/fncir.2013.00142 PMID: 24065890

31. Loddenkemper T, Talos DM, Cleary RT, Joseph A, Sanchez Fernandez I, et al. (2014) Subunit composition of glutamate and gamma-aminobutyric acid receptors in status epilepticus. Epilepsy Res 108: 605–615. doi: 10.1016/j.eplepsyres.2014.01.015 PMID: 24613745

32. Loup F, Picard F, Yonekawa Y, Wieser HG, Fritschy JM (2009) Selective changes in GABAA receptor subtypes in white matter neurons of patients with focal epilepsy. Brain 132: 2449–2463. doi: 10.1093/brain/awp178 PMID: 19574438

33. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, et al. (2007) A survey of genetic human cortical gene expression. Nat Genet 39: 1494–1499. doi: 10.1038/ng.2007.16 PMID: 17982457

34. Mulligan MK, Wang X, Adler AL, Mozholi K, Lu L, et al. (2012) Complex Control of GABA(A) Receptor Subunit mRNA Expression: Variation, Covariation, and Genetic Regulation. PLoS ONE 7: e34586. doi: 10.1371/journal.pone.0034586 PMID: 22506031

35. Yeo S, Hodgkinson CA, Zhou Z, Jung J, Leung M, Yuan Q, Goldman D (2016) The abundance of cis-acting loci leading to differential allele expression in F1 mice and their relationship to loci harboring genes affecting complex traits. BMC Genomics 17: 620. doi: 10.1186/s12864-016-2922-9 PMID: 27515598

36. Ellenberger HH (1999) Distribution of bulbospinal gamma-aminobutyric acid-synthesizing neurons of the ventral respiratory group of the rat. Journal of Comparative Neurology 411: 130–144. PMID: 10404112

37. Frank JG, Jameson HS, Gorini C, Mendelowitz D (2009) Mapping and identification of GABAergic neurons in transgenic mice projecting to cardiac vagal neurons in the nucleus ambiguous using photo-uncaging. J Neurophysiol 101: 1755–1760. doi: 10.1152/jn.91134.2008 PMID: 19164103

38. Massey CA, Sowers LP, Dlouhy BJ, Richerson GB (2014) Mechanisms of sudden unexpected death in epilepsy: the pathway to prevention. Nat Rev Neurol 10: 271–282. doi: 10.1038/nrneurol.2014.64 PMID: 24752120

39. Nashef L, Hindocha N, Makoff A (2007) Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms. Epilepsia 48: 859–871. doi: 10.1111/j.1528-1167.2007.01082.x PMID: 17433051

40. Kalume F, Westenbroek RE, Cheah CS, Yu FH, Oakley JC, et al. (2013) Sudden unexpected death in a mouse model of Dravet syndrome. J Clin Invest 123: 1798–1808. doi: 10.1172/JCI66220 PMID: 23524966
41. Deidda G, Bozarth IF, Cancetta L (2014) Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci 8: 119. doi: 10.3389/fncel.2014.00119 PMID: 24904277

42. Ceulemans B, Boel M, Claes L, Dom L, Willekens H, et al. (2004) Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol 19: 516–521. PMID: 15526956

43. Shi X-Y, Tomonoh Y, Wang W-Z, Ishii A, Higurashi N, et al. (2016) Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. Brain and Development 38: 40–46. doi: 10.1016/j.braindev.2015.06.008 PMID: 26183863

44. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, et al. (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356: 1638–1642. PMID: 11089822

45. Giraud C, Treluyer J-M, Rey E, Chiron C, Vincent J, et al. (2006) In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metabolism and Disposition 34: 608–611. doi: 10.1124/dmd.105.007237 PMID: 16415114

46. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, et al. (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456: 53–59. doi: 10.1038/nature07517 PMID: 18987734

47. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, et al. (2010) Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol Chapter 19: 1–21.

48. Giardine B, Riemer C, Hardison RC, Burhans R, Elnitski L, et al. (2005) Galaxy: a platform for interactive large-scale genome analysis. Genome Res 15: 1451–1455. doi: 10.1101/gr.4086505 PMID: 16169926

49. Goecks J, Nekrutenko A, Taylor J (2010) Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 11.

50. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, et al. (2013) TopHat2: accurate alignment of transcripts in the presence of insertions, deletions and gene fusions. Genome Biol 14: R36. doi: 10.1186/gb-2013-14-4-r36 PMID: 23618408

51. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, et al. (2015) StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol 33: 290–295. doi: 10.1038/nbt.3122 PMID: 25690850

52. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511–515. doi: 10.1038/nbt.1621 PMID: 20436464

53. Yates A, Akanni W, Ridwan Amode M, Barrett D, Billis K, et al. (2016) Ensembl 2016. Nucleic Acids Res 44: D710–716. doi: 10.1093/nar/gkv1157 PMID: 26687719